Chandelier
Senior Member (Voting Rights)
The NLRP3 inflammasome as a key pathway in the affective and chronic fatigue symptoms of Long COVID - Journal of Translational Medicine
The neuropsychiatric and somatic manifestations (physio-affective phenome) of Long COVID are substantially predicted by elevated peak body temperature (PBT
link.springer.com
Authors: Yingqian Zhang, Hussein Kadhem Al-Hakeim, Hawraa Kadhem Al-Jassas & Michael Maes
Abstract
Background
The neuropsychiatric and somatic manifestations (physio-affective phenome) of Long COVID are substantially predicted by elevated peak body temperature (PBT) and diminished oxygen saturation (SpO2) during the acute infectious stage.The latter is linked to the immune pathophysiology of Long COVID involving activation of the immune-inflammatory response system (IRS) and the nucleotide-binding domain leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome.
Nevertheless, there is a lack of data indicating whether NLRP3 and its components are implicated in the physio-affective phenome of Long COVID.
Method
We enrolled 161 Long COVID patients 6 to 9 months after the acute phase and divided them into two groups based on their baseline PBT and SpO2 levels, corresponding to mild and severe acute COVID-19.We assessed serum NLRP3, caspase-1, C-reactive protein (CRP), interleukin (IL)-18, IL-1β, IL-10, fibronectin, and Gasdermin D (GSDMD) during Long COVID.
Results
All of the aforementioned indicators (except IL-10) were substantially higher in Long COVID patients who had previously experienced severe COVID-19 than in those who had mild acute COVID-19.The physio-affective phenome of Long COVID and the severity of the acute COVID-19 were significantly correlated with these IRS biomarkers, with the exception of fibronectin.
The variance in the overall severity of Long COVID is accounted for (49.5%) by the combined influence of fibronectin, IL-10, SpO2, and PBT.
Conclusion
The severity of Long COVID is strongly associated with IRS and NLRP3 activation and the severity of the inflammatory response during the acute infectious phase.NLRP3 activation is a drug target to treat Long COVID.
DOI: 10.1186/s12967-026-07703-3
